Pricing Log in Create free account
Friday 6 November 2026 Export PHR’s income statement to Excel — free account

Phreesia, Inc.

PHR Healthcare Health Information Services

Phreesia, Inc.’s revenue for fiscal 2026 (year ended January 2026) was $480.6 million, up 14.5% from fiscal 2025.

Revenue
+10.4%
EPS
+200.0%
Free cash flow
+43.5%
Total debt
+3,191.9%

Quarter to July 2026, against a year earlier

12.56 0.15 −1.18%
Market cap
$788.9M
P/E
74.4×
Fwd P/E
40.2×
Dividend yield
—
F-score
5/9
Altman Z
0.65
Beneish M
−2.15
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Bought, $m 28.77
Sold, $m 1.96
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — 2 — — — — — — 1 —
Sell 2 14 — 3 5 1 1 3 — 1 — —
Insider Ownership 8.19%

Capital & Financial Ratios $m

Size
Market Cap 788.93
Revenue ttm 507.79
Net income ttm 10.45
Free cash flow ttm 67.52
Net debt Q 77.69
Valuation
P/E 74.35 (above 35: high)
Forward P/E 40.20 (above 35: high)
Price / sales 1.54
Forward P/S Powerpack
Price / FCF 11.58
Price / book 2.10
Financial health
Current ratio Q 1.76 (at or above 1.5: strong)
Debt / equity Q 0.41 (at or below 0.5: strong)
Interest coverage Q 4.40
Growth
Revenue growth Q +10.41% (above 0%: growing)
Operating income growth Q +604.84% (above 0%: growing)
EPS, this year +634.57% (at or above 15%: strong)
EPS, next year A +124.62% (at or above 15%: strong)
Revenue, next year A +7.33%
EPS, past 5 yrs —
EPS, next 5 yrs A +165.29% (at or above 15%: strong)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 1.7×, against a ten-year median of 4.0×; over the ten years it ranged from 0.8× in 2019 to 17.8× in 2021.
P/S against its own 10 years 10.18%
10-year low 10-year high
P/B against its own 10 years 12.96%
10-year low 10-year high
EV/Sales against its own 10 years 13.02%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2024 2025 2026 Q'26
Cash 88 84 74 73
Receivables 65 74 155 134
Inventory — — — —
Other 28 29 33 27
196 203 280 254
2024 2025 2026 Q'26
Payables 8 6 11 12
ST’ Debt — — 38 30
Other 34 29 34 27
110 114 183 144

Compound Annual Growth %

10y 5y 3y
Sales — 26.45% 19.60%
Cash Flow — 93.71% 0.00%
Earnings — 0.00% 0.00%
Book Value — 5.07% 5.42%

Earnings Trends EPS, adjusted, against the consensus

Q2 FY27 Estimate 0.11 Actual 0.03

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q3 FY26 0.00 0.10 Beat by 0.10
Q4 FY26 0.09 0.12 Beat by 0.03
Q1 FY27 0.02 0.05 Beat by 0.03
Q2 FY27 0.11 0.03 Miss by 0.08
Q3 FY27 0.13 — Reports 14 December 2026

EPS $

Apr Jul Oct Jan Year
’26 0.05 0.03 — — —
’26 (0.07) 0.01 0.07 0.02 0.04
’25 (0.35) (0.31) (0.25) (0.11) (1.02)
’24 (0.70) (0.68) (0.58) (0.56) (2.51)
’23 (0.99) (0.89) (0.76) (0.72) (3.36)
’22 (0.24) (0.48) (0.71) (0.90) (2.37)
’21 (0.16) (0.17) (0.17) (0.18) (0.69)
Fiscal quarters ending in the months shown.

Revenue $m

Apr Jul Oct Jan Year
’26 131 129 — — —
’26 116 117 120 127 481
’25 101 102 107 110 420
’24 84 86 92 95 356
’23 63 68 73 77 281
’22 48 51 56 58 213
’21 33 35 38 42 149
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Apr Jul Oct Jan Year
’26 24 18 — — —
’26 15 15 15 34 79
’25 (1) 11 6 16 32
’24 (14) (9) (6) (3) (32)
’23 (34) (20) (21) (16) (90)
’22 (5) (7) (25) (38) (75)
’21 2 (2) (1) 4 3
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Apr Jul Oct Jan Year
’26 16 14 — — —
’26 7 10 9 29 54
’25 (6) 4 2 9 8
’24 (20) (15) (12) (11) (57)
’23 (41) (26) (27) (22) (116)
’22 (12) (10) (39) (44) (106)
’21 (1) (7) (4) (3) (16)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.9
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to January

Ten-year view Analyst estimates Powerpack
Group Line 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 TTM Jul ’26 Trend 10 yrs 2027e 2028e 2029e Next 3/yr
Income, $m
Income, $m Revenue — 80 100 125 149 213 281 356 420 481 508 +25.2% 516 535 559 +5.1%
Gross margin, % — 62.71 62.96 64.16 64.77 61.83 61.10 65.19 67.86 67.93 67.52 +5.2 pt
EBT — (18) (15) (22) (27) (118) (176) (135) (56) (9) 3 (8.5%)
EBT margin, % — (22.79) (15.08) (17.69) (18.32) (55.33) (62.53) (37.99) (13.29) (1.86) 0.54 +20.9 pt
Net income — (18) (15) (20) (27) (118) (176) (137) (59) 2 10 n/m
Per share, $
Per share, $ Revenue — 51.87 54.14 6.15 3.76 4.27 5.36 6.53 7.29 8.05 8.21 (20.8%)
Earnings — (24.81) (24.53) (4.50) (0.69) (2.37) (3.36) (2.51) (1.02) 0.04 0.17 n/m
Cash flow — (7.24) (1.15) 0.04 0.07 (1.50) (1.72) (0.59) 0.56 1.32 1.48 n/m
Capex — (7.77) (5.33) (0.61) (0.47) (0.62) (0.50) (0.46) (0.42) (0.41) (0.39) (30.8%)
Free cash flow — (15.01) (6.48) (0.57) (0.40) (2.11) (2.22) (1.05) 0.14 0.91 1.09 n/m
Book value — 0.00 (2.43) 5.02 6.66 8.36 5.49 4.61 4.60 5.64 6.01 n/m
Shares, m — 2 2 20 40 50 52 55 58 60 61 +58.0%
Valuation, ×
Valuation, × P/E — 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 440.33 74.35 48.9
P/S — 0.00 0.00 5.04 17.74 7.30 7.00 3.90 3.90 1.64 1.54 5.2
P/B — 0.00 0.00 6.18 10.02 3.73 6.83 5.53 6.19 2.34 2.10 4.5
EV/Sales — 0.00 0.00 4.51 16.35 5.89 6.40 3.69 3.74 1.85 1.69 4.7
EV/FCF — (6.27) (6.27) (48.97) (155.00) (11.91) (15.46) (22.89) 189.37 16.37 12.73 (6.8)
Cash, $m
Cash, $m Operating cash flow — (11) (2) 1 3 (75) (90) (32) 32 79 91 n/m
Capex — (12) (10) (12) (19) (31) (26) (25) (24) (24) (24) +9.3%
Free cash flow — (23) (12) (11) (16) (106) (116) (57) 8 54 68 n/m
Balance, $m
Balance, $m Working capital — 9 5 96 217 318 183 86 89 97 110 +33.9%
Net debt — 146 29 (66) (206) (299) (168) (82) (76) 102 78 (4.4%)
Shareholders’ equity — — (4) 102 263 417 288 251 265 337 372 n/m
Returns, %
Returns, % ROA — (65.59) (152.75) (83.87) (11.24) (28.78) (40.75) (36.98) (15.43) 0.44 1.98 +66.0 pt
ROIC — (6.22) (24.33) (27.00) (28.17) (61.88) (91.98) (50.37) (19.24) (0.94) 1.74 +5.3 pt
ROE — 20.16 23.91 167.58 (14.95) (34.72) (49.96) (50.77) (22.67) 0.77 3.12 (19.4) pt
People
People Employees — — 436 532 827 1,701 1,546 1,438 2,082 1,789 — +22.3%
Revenue/emp, $m — 0.00 0.23 0.23 0.18 0.13 0.18 0.25 0.20 0.27 — n/m
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Jan 2026 · latest quarter Jul 2026 · fundamentals updated 26 Oct 2026

Phreesia, Inc. vs peers in Health Information Services (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
CERT Certara, Inc. $1.9B — (loss-making) — (loss-making) −9.29% (below 0%: shrinking) +300.00% (above 0%: growing) −12.09% (below 0%: shrinking) 66.87% 2.45% Compare
GDRX GoodRx Holdings, Inc. $1.2B 65.7× 46.0× −1.31% (below 0%: shrinking) −25.00% (below 0%: shrinking) +112.45% (above 0%: growing) 89.52% 11.79% Compare
OMDA Omada Health, Inc. $1.2B 267× 156× +43.12% (above 0%: growing) n/m +45.71% (above 0%: growing) 72.62% 4.04% Compare
HSTM HealthStream, Inc. $905.6M 42.0× 45.4× +8.94% (above 0%: growing) −8.90% (below 0%: shrinking) −4.80% (below 0%: shrinking) 63.98% 7.91% Compare
PHR Phreesia, Inc. $788.9M 74.4× 40.2× +10.41% (above 0%: growing) +200.00% (above 0%: growing) +43.51% (above 0%: growing) 66.64% 5.88%
NRC National Research Corporation $563.6M 87.6× 61.1× +10.95% (above 0%: growing) +22.22% (above 0%: growing) −31.38% (below 0%: shrinking) 59.95% 23.20% Compare
SOPH SOPHiA GENETICS SA $563.6M — (loss-making) — (loss-making) +24.69% (above 0%: growing) n/m −1.87% (below 0%: shrinking) 65.66% (73.45%) Compare
EVH Evolent Health, Inc $513.3M — (loss-making) — (loss-making) +51.27% (above 0%: growing) n/m +179.84% (above 0%: growing) 12.19% (0.85%) Compare
CARL Carlsmed, Inc. $418.3M — (loss-making) — (loss-making) +56.75% (above 0%: growing) n/m −6.84% (below 0%: shrinking) 76.78% (58.27%) Compare
Median of peers $734.6M 76.6× 53.6× +17.82% +6.66% −3.34% 66.27% 3.25%

All 44 Health Information Services stocks →

Pay and ownership Proxy statement filed 14 May 2026

Chief executive’s pay

Year Total pay Actually paid $100 invested
2026 8.08m (17.94m) 20.57
2025 10.51m 11.79m 91.81
2024 8.27m (240.00k) 82.19
2023 7.60m 12.51m 120.94
2022 8.92m (15.02m) 100.61

Ownership

Directors and executive officers, together 5.20%
Pale Fire Capital SE 14.40%
BlackRock, Inc. 6.70%
Vanguard Portfolio Management 5.60%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Phreesia, Inc. (PHR) Latest News

6 Oct

Impact 3 · · Business Wire

30 Sep

Impact 3 · · Business Wire

17 Sep

Impact 3 ·

14 Sep

Impact 3 ·

13 Sep

Impact 3 ·

9 Sep

Impact 3 · · The Motley Fool transcript

3 Sep

Impact 4 · transcript
Impact 3 · · The Motley Fool
Impact 3 · · Moby transcript

2 Sep

Impact 3 · · MarketBeat
Impact 3 ·
Impact 3 ·

21 Jul

Impact 3 ·

10 Jun

Impact 3 · · Simply Wall St.

4 Jun

Impact 3 · · Insider Monkey

28 May

Impact 4 · · GuruFocus.com transcript

27 May

Impact 4 · · The Motley Fool transcript
Impact 3 · · Moby
Impact 3 · · MarketBeat transcript
Impact 3 · · Zacks
Impact 3 · · Business Wire

20 May

Impact 3 · · The Motley Fool

19 May

Impact 3 · · Simply Wall St.

8 May

Impact 4 · · Insider Monkey

2 Apr

Impact 4 · · Simply Wall St.
Impact 3 · · MarketBeat

1 Apr

Impact 4 · · Barrons.com

31 Mar

Impact 4 · · Investing.com
Impact 3 · · The Motley Fool

30 Mar

Impact 4 · · GuruFocus.com
stockrow.com/PHR · Data as of Oct 26, 2026 · For information only; not investment advice. · © 2026 stockrow.com